RICI HEALTHCARE HOLDINGS LIMITED

瑞慈醫療服務控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1526)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL SUMMARY

- Revenue for the six months ended June 30, 2026 amounted to RMB1,138.6 million, representing a decrease of 0.5% from that of RMB1,144.8 million for the corresponding period in 2025.
- Gross profit for the six months ended June 30, 2026 amounted to RMB397.1 million, as compared to RMB407.6 million for the corresponding period in 2025.
- Profit attributable to owners of the Company for the six months ended June 30, 2026 amounted to RMB45.5 million, as compared to RMB55.9 million for the corresponding period in 2025.
- The adjusted EBITDA amounted to RMB339.9 million during the Reporting Period, as compared to RMB386.6 million for the corresponding period in 2025.[(1)]
- The Board has resolved not to declare any interim dividend for the Reporting Period.

Note:

(1) Adjusted EBITDA is defined as profit for the period before certain expenses and depreciation and amortization, for further details, please refer to page 36 of this announcement.

In this announcement, "we", "us", "our" and "Rici" refer to the Company (as defined below) and where the context otherwise requires, the Group (as defined below).

The board (the "**Board**") of directors (the "**Directors**") of Rici Healthcare Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces the unaudited consolidated financial results of the Group for the six months ended June 30, 2026 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2025. The Group's unaudited interim condensed consolidated balance sheet, unaudited interim condensed consolidated statement of profit or loss, unaudited interim condensed consolidated statement of other comprehensive income and explanatory notes 1 to 20 as presented below are extracted from the Group's unaudited interim condensed consolidated financial information for the six months ended June 30, 2026.

Interim condensed consolidated balance sheet

As at June 30, 2026

	Notes	Unaudited 30 June 2026 RMB'000	Audited 31 December 2025 RMB'000
ASSETS			
Non-current assets			
Property and equipment		**1,379,944**	1,422,827
Right-of-use assets	*5*	**1,090,150**	1,148,344
Intangible assets		**14,125**	13,461
Investments accounted for using equity method		**1,542**	1,872
Financial assets at fair value through other comprehensive income		**178,090**	162,100
Deposits for long-term leases		**71,143**	70,403
Deferred tax assets	*6*	**124,539**	91,332
Prepayments	*9*	**217,746**	214,602
		3,077,279	3,124,941
Current assets			
Inventories		**26,865**	29,394
Trade receivables	*7*	**247,400**	286,060
Other receivables		**208,304**	230,664
Prepayments	*9*	**32,177**	27,674
Financial assets at fair value through profit or loss		**28,743**	10,163
Deposits in financial institution		**7,958**	18,065
Restricted cash	*8(b)*	**996**	15,994
Cash and cash equivalents	*8(a)*	**1,065,317**	1,135,425
		1,617,760	1,753,439
Total assets		**4,695,039**	4,878,380

	Notes	Unaudited 30 June 2026 *RMB'000*	Audited 31 December 2025 *RMB'000*
EQUITY			
Equity attributable to owners of the Company			
Share capital	*10*	**1,065**	1,065
Reserves		**1,676,464**	1,645,006
		1,677,529	1,646,071
Non-controlling interests		**24,135**	73,738
Total equity		**1,701,664**	1,719,809
LIABILITIES			
Non-current liabilities			
Borrowings	*11*	**224,875**	242,450
Lease liabilities	*12*	**1,061,927**	1,114,059
Deferred income		**3,031**	4,207
		1,289,833	1,360,716
Current liabilities			
Borrowings	*11*	**345,150**	393,150
Lease liabilities	*12*	**266,276**	262,449
Contract liabilities	*13*	**651,719**	608,612
Trade and other payables	*14*	**402,805**	475,994
Amount due to related parties		**984**	—
Income tax payables		**32,869**	54,468
Deferred income		**3,739**	3,182
		1,703,542	1,797,855
Total liabilities		**2,993,375**	3,158,571
Total equity and liabilities		**4,695,039**	4,878,380

Interim condensed consolidated statement of profit or loss

For the six months ended 30 June 2026

	Notes	Unaudited	Unaudited
		Six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
Revenue	*15*	**1,138,578**	1,144,849
Cost of sales	*16*	**(741,475)**	(737,259)
Gross profit		**397,103**	407,590
Distribution costs and selling expenses	*16*	**(190,284)**	(134,471)
Administrative expenses	*16*	**(105,831)**	(116,740)
Reversal of impairment losses/(impairment losses) on financial assets	*16*	**1,222**	(2,543)
Other income		**23,219**	20,978
Other losses		**(79)**	(5,855)
Change in fair value of financial assets at fair value through profit or loss		**7,122**	—
Operating profit		**132,472**	168,959
Finance costs	*17*	**(44,866)**	(53,300)
Finance income	*17*	**1,003**	3,214
Finance costs — net		**(43,863)**	(50,086)
Share of results of investments accounted for using equity method		**(330)**	568
Profit before income tax		**88,279**	119,441
Income tax expense	*18*	**(23,143)**	(39,696)
Profit for the period		**65,136**	79,745
Profit attributable to:			
Owners of the Company		**45,547**	55,941
Non-controlling interests		**19,589**	23,804
		65,136	79,745
Earnings per share for profit attributable to owners of the Company			
— Basic and diluted	*19*	**RMB0.03**	RMB0.04

Interim condensed consolidated statement of other comprehensive income
For the six months ended 30 June 2026

	Unaudited	Unaudited
	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Profit for the period	**65,136**	79,745
Other comprehensive income or loss		
Item will not be subsequently reclassified to profit or loss		
— Change in fair value of financial assets at fair value through other comprehensive income	**15,990**	(1,000)
Total comprehensive income for the period	**81,126**	78,745
Total comprehensive income for the period is attributable to:		
Owners of the Company	**61,537**	54,941
Non-controlling interests	**19,589**	23,804
	81,126	78,745

Notes to the interim condensed consolidated financial information

For the six months ended 30 June 2026

1 General information

Rici Healthcare Holdings Limited (the "**Company**") was incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law (2013 Revision) of the Cayman Islands on 11 July 2014. The address of the Company's registered office is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.

The Company, an investment holding company and its subsidiaries (collectively, the "**Group**") are principally engaged in the provision of general hospital services and medical examination services in the People's Republic of China ("**PRC**").

The Company's shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 6 October 2016.

The interim condensed consolidated financial information is presented in thousands of Renminbi ("**RMB'000**"), unless otherwise stated, and was approved and authorised for issue by the board of directors (the "**Board**") of the Company on 28 August 2026.

2 Basis of preparation

This interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with HKAS 34 "Interim Financial Reporting", and does not include all the notes of the type normally included in an annual financial statements. The interim condensed consolidated financial information should be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2025, which have been prepared in accordance with HKFRS Accounting Standards and together with any public announcements made by the Company.

Going concern

As at 30 June 2026, the Group's current liabilities exceeded its current assets by RMB85,782,000. Contract liabilities and deferred income included in current liabilities of the Group as at 30 June 2026 amounting to RMB655,458,000 in aggregate are not expected to create cash outflow for the Group. The Group meets its day-to-day working capital requirements depending on cash flows generated from operating activities, bank borrowings and unutilised banking facilities provided by banks in the PRC. Based on the Group's past experience and good credit standing, the directors are confident on future operating cash flows and that the Group's bank financing could be renewed and/or extended for at least another twelve months upon maturity, as and when necessary. The directors therefore are of the opinion that it is appropriate to adopt the going concern basis in preparing the interim condensed consolidated financial information.

3 Accounting policies

The accounting policies applied in the preparation of the interim condensed consolidated financial information are consistent with those of the annual financial statements of the Group for the year ended 31 December 2025, as described in those annual financial statements, except for the adoption of new and amended standards, as set out below.

(a) Amended standards adopted by the Group

- Amendments to HKAS 21 — Lack of Exchangeability

The amended standards listed above did not have any impact on the amounts recognised in prior years and are not expected to materially affect the current or future reporting period.

(b) New and revised standards and interpretations not yet adopted

Certain new and amendments of HKFRS Accounting Standards have been published but are not mandatory for the financial year beginning 1 January 2026 and have not been early adopted by the Group.

		Effective for annual periods beginning on or after
HKFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
HKFRS 19 and its amendments	Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to Illustrative Examples on HKFRS 7, HKFRS 18, HKAS 1, HKAS 8, HKAS 36 and HKAS 37	Disclosures about Uncertainties in the Financial Statements	1 January 2027
Amendments to HKAS 28	Disclosures about Uncertainties in the Financial Statements	1 January 2027
Amendments to HKAS 21	Fair Value Option for Investments in Associates and Joint Ventures	1 January 2027
HKFRS 20	Regulatory Assets and Regulatory Liabilities	1 January 2029
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

4 Segment information

Management has determined the operating segments based on the information reviewed by the chief operating decision-maker ("**CODM**") for the purpose of corporate planning, allocating resources and assessing performance.

Management considers the business from a business perspective, and assesses the performance of the business segment based on segment profit without allocation of administrative expenses, reversal of impairment losses on financial assets, net impairment losses on financial assets, interest income, interest expenses, net exchange losses, net exchange gains, other income, other losses, share of result of investments accounted for using equity method and income tax expense.

The amounts provided to management with respect to total assets and total liabilities are measured consistent with that of the financial information. These assets are allocated based on the operations of segments. Certain assets and liabilities related to some subsidiaries with corporate function are not allocated into segments. Elimination of revenue are mainly inter-segment service charges related to general hospital business.

The Group manages its business by two operating segments based on their services, which is consistent with the way in which information is reported internally to the Group's CODM for the purpose of resources allocation and performance assessment. The principal assets employed by the Group are located in the PRC, and accordingly, no geographical segment analysis has been prepared.

(a) General hospital

The business of this segment is in Nantong, a city of Jiangsu Province. Revenue from this segment is derived from general hospital services provided by Nantong Rich Hospital Co., Ltd. ("**Nantong Rich Hospital**"), maternity care services provided by Nantong Advanced Hejia Maternity and Child Nursing Service Co., Ltd, and elderly care services provided by Nantong Rich Meidi Elderly Care Centre Co., Ltd. ("**Nantong Meidi**").

(b) Medical examination centers

The business of this segment is in Shanghai city, Jiangsu Province and other provinces in the PRC. Revenue from this segment is derived from medical examination services.

The following table presents revenue and profit information regarding the Group's operation segments for the six months ended 30 June 2026 and 2025, and the segment assets and liabilities as at 30 June 2026 and 31 December 2025.

Revenue between segments are carried out at arm's length and are eliminated on consolidation. The revenue from external parties is measured in the same way as in the interim condensed consolidated statement of profit or loss.

	General Hospital *RMB'000*	Medical Examination Centers *RMB'000*	Unallocated *RMB'000*	Elimination *RMB'000*	Total *RMB'000*
For the six months ended 30 June 2026 (unaudited)					
Revenue	**219,362**	**927,552**	**—**	**(8,336)**	**1,138,578**
Segment profit/(loss)	**31,284**	**175,862**	**(327)**	**—**	**206,819**
Administrative expenses					**(105,831)**
Reversal of impairment losses on financial assets					**1,222**
Interest income					**1,003**
Interest expenses					**(42,527)**
Net exchange losses					**(2,339)**
Other income					**23,219**
Other losses					**(79)**
Share of result of investments accounted for using equity method					**(330)**
Change in fair value of financial assets at fair value through profit or loss					**7,122**
Profit before income tax					**88,279**
Income tax expense					**(23,143)**
Profit for the period					**65,136**

	General Hospital *RMB'000*	Medical Examination Centers *RMB'000*	Subtotal *RMB'000*	Unallocated *RMB'000*	Elimination *RMB'000*	Total *RMB'000*
As at 30 June 2026 (unaudited)						
Segment assets	1,224,832	4,073,231	5,298,063	950,521	(1,553,545)	4,695,039
Segment liabilities	523,065	2,666,036	3,189,101	370,327	(566,053)	2,993,375
For the six months ended 30 June 2026 (unaudited)						
Other information						
Additions to property and equipment, right-of-use assets and intangible assets	7,156	159,042	166,198	–	–	166,198
Depreciation and amortisation	23,667	180,289	203,956	50	–	204,006

	General Hospital *RMB'000*	Medical Examination Centers *RMB'000*	Unallocated *RMB'000*	Elimination *RMB'000*	Total *RMB'000*
For the six months ended 30 June 2025 (unaudited)					
Revenue	234,004	925,129	—	(14,284)	1,144,849
Segment profit/(loss)	33,258	241,539	(1,678)	—	273,119
Administrative expenses					(116,740)
Net of impairment losses on financial assets					(2,543)
Interest income					3,214
Interest expenses					(53,239)
Net exchange losses					(61)
Other income					20,978
Other losses					(5,855)
Share of result of investments accounted for using equity method					568
Profit before income tax					119,441
Income tax expense					(39,696)
Profit for the period					79,745

	General Hospital *RMB'000*	Medical Examination Centers *RMB'000*	Unallocated *RMB'000*	Elimination *RMB'000*	Total *RMB'000*
For the six months ended 30 June 2025 (unaudited)					
Segment assets	1,285,877	4,168,976	1,026,903	(1,764,972)	4,716,784
Segment liabilities	590,167	3,065,492	411,629	(767,397)	3,299,891
For the six months ended 30 June 2025 (unaudited)					
Other information					
Additions to property and equipment, right-of-use assets and intangible assets	13,969	161,118	—	—	175,087
Depreciation and amortisation	24,740	186,646	50	—	211,436

5 Right-of-use assets

	Unaudited As at 30 June 2026 ***RMB'000***	Audited As at 31 December 2025 *RMB'000*
Properties	**1,087,602**	1,145,746
Land use rights	**2,548**	2,598
	1,090,150	1,148,344

	Properties *RMB'000*	Land use rights *RMB'000*	Total *RMB'000*
As at 1 January 2026 (Audited)			
Cost	**1,991,009**	**4,698**	**1,995,707**
Accumulated depreciation	**(845,263)**	**(2,100)**	**(847,363)**
Net book amount	**1,145,746**	**2,598**	**1,148,344**
Six months ended 30 June 2026 (Unaudited)			
Opening net book amount	**1,145,746**	**2,598**	**1,148,344**
Additions	**105,712**	**—**	**105,712**
Modification	**(30,664)**	**—**	**(30,664)**
Termination	**(30,451)**	**—**	**(30,451)**
Depreciation	**(102,741)**	**(50)**	**(102,791)**
Closing net book amount	**1,087,602**	**2,548**	**1,090,150**
As at 30 June 2026 (Unaudited)			
Cost	**1,979,112**	**4,698**	**1,983,810**
Accumulated depreciation	**(891,510)**	**(2,150)**	**(893,660)**
Net book amount	**1,087,602**	**2,548**	**1,090,150**

	Properties	Land use rights	Total
	RMB'000	*RMB'000*	*RMB'000*
As at 1 January 2025 (Audited)			
Cost	1,976,479	4,698	1,981,177
Accumulated depreciation	(681,630)	(2,000)	(683,630)
Net book amount	1,294,849	2,698	1,297,547
Six months ended 30 June 2025 (Unaudited)			
Opening net book amount	1,294,849	2,698	1,297,547
Additions	122,052	—	122,052
Modification	(22,539)	—	(22,539)
Termination	(29,029)	—	(29,029)
Depreciation	(107,163)	(50)	(107,213)
Closing net book amount	1,258,170	2,648	1,260,818
As at 30 June 2025 (Unaudited)			
Cost	2,033,489	4,698	2,038,187
Accumulated depreciation	(775,319)	(2,050)	(777,369)
Net book amount	1,258,170	2,648	1,260,818

As at 30 June 2026, land with a total carrying amount of RMB2,548,000 (31 December 2025: RMB2,598,000) were pledged for the Group's borrowings.

6 Deferred tax assets

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
The balance comprises temporary differences attributable to:		
Tax losses	**52,704**	19,055
Right-of-use assets and lease liabilities	**46,602**	46,285
	99,306	65,340
Share option scheme	**21,882**	21,882
Loss allowances for financial assets	**2,511**	3,269
Impairment of property and equipment	**840**	841
	25,233	25,992
Total deferred tax assets	**124,539**	91,332

7 Trade receivables

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Trade receivables	**260,087**	299,328
Less: Loss allowance	**(12,687)**	(13,268)
	247,400	286,060

As at 30 June 2026 and 31 December 2025, the fair value of trade receivables of the Group approximated to their carrying amount.

The aging analysis of trade receivables based on the date the relevant service was rendered is as follows:

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Trade receivables		
— Up to 6 months	**236,379**	285,448
— 6 months to 1 year	**18,232**	6,888
— 1 to 2 years	**2,969**	4,405
— 2 to 3 years	**462**	802
— Over 3 years	**2,045**	1,785
	260,087	299,328

8 Cash and bank balances

(a) Cash and cash equivalents

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Cash at bank and on hand		
— Denominated in RMB	**1,022,816**	1,085,609
— Denominated in USD	**23,735**	42,774
— Denominated in HKD	**18,766**	7,042
	1,065,317	1,135,425

(b) Restricted cash

The amount of RMB996,000 is a security deposit for the letter of guarantee from the banks (31 December 2025: RMB15,994,000) for the daily operation of the Group as at 30 June 2026.

9 Prepayments

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Non-current:		
Deposit for purchase of investment property	**198,951**	198,951
Prepayments for property and equipment	**18,795**	15,651
	217,746	214,602
Current:		
Prepayments for consumables	**28,586**	13,014
Others *(Note)*	**3,591**	14,660
	32,177	27,674
Total prepayments	**249,923**	242,276

Note:

Others mainly included prepaid advertising expenses and prepaid property management fee.

10 Share capital

Ordinary shares, issued and fully paid:

	Number of ordinary shares	**Share capital** *RMB'000*
As at 30 June 2026 and 31 December 2025	1,590,324,000	1,065

11 Borrowings

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Bank borrowings-secured and/or guaranteed	**570,025**	635,600
Less: Non-current portion of non-current borrowings	**(224,875)**	(242,450)
	345,150	393,150

All the borrowings are denominated in RMB and their fair value approximated to their carrying amounts.

12 Lease liabilities

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Present value of the minimum lease payments:		
Within 1 year	**266,276**	262,449
After 1 year but within 2 years	**221,835**	235,768
After 2 years but within 5 years	**495,684**	497,107
After 5 years	**344,408**	381,184
	1,328,203	1,376,508

13 Contract liabilities

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Sales of medical examination cards	**586,136**	588,824
Advances from medical examination customers	**52,064**	10,606
Advances from hospital patients	**13,519**	9,182
	651,719	608,612

14 Trade and other payables

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Trade payables due to third parties	**144,512**	155,462
Payables for purchase of property and equipment	**54,070**	79,811
Staff salaries and welfare payables	**67,509**	108,227
Deposits received	**26,491**	26,246
Accrued taxes other than income tax	**4,721**	6,651
Accrued professional service fees	**2,021**	3,206
Interest payables	**435**	468
Dividend payables	**27,601**	—
Accrued advertising expenses	**391**	357
Others	**75,054**	95,566
	402,805	475,994

The aging analysis of the trade payables based on invoice date is as follows:

	Unaudited As at 30 June 2026 *RMB'000*	Audited As at 31 December 2025 *RMB'000*
Trade payables		
— Up to 3 months	**109,754**	133,395
— 3 to 6 months	**14,353**	4,207
— 6 months to 1 year	**4,543**	3,324
— 1 to 2 years	**3,659**	2,161
— 2 to 3 years	**4,121**	3,492
— Over 3 years	**8,082**	8,883
	144,512	155,462

The trade payables are usually paid within 30–60 days of recognition.

The fair value of all trade and other payables of the Group approximated to their carrying amounts and the carrying amounts of the Group's trade and other payables are denominated in RMB.

15 Revenue

Revenue of the Group consists of the following:

	Unaudited Six months ended 30 June	
	2026 *RMB'000*	2025 *RMB'000*
General hospital		
Outpatient pharmaceutical revenue	**21,665**	21,834
Outpatient service revenue	**30,630**	27,988
Inpatient pharmaceutical revenue	**43,666**	62,365
Inpatient service revenue	**115,065**	107,533
Medical examination centers		
Examination service revenue	**927,371**	924,923
Management service revenue and others	**181**	206
	1,138,578	1,144,849

16 Expenses by nature

	Unaudited	
	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Employee benefits expenses	**551,574**	469,101
Depreciation and amortization	**204,006**	211,436
Pharmaceutical costs	**38,546**	55,549
Medical consumables costs	**59,397**	51,788
Outsourcing testing expenses	**40,486**	49,140
Utility expenses	**49,609**	45,512
Office expenses	**6,693**	14,867
Maintenance expenses	**11,997**	18,046
Short-term or low-value operating lease rentals	**5,558**	5,517
Platform service charges	**29,267**	29,612
Professional service charges	**6,030**	5,169
Entertainment expenses	**2,753**	6,242
Stamp duty and other taxes	**4,715**	4,500
Advertising expenses	**12,849**	11,505
Labour union dues	**1,123**	1,298
Travel expenses	**3,744**	2,174
(Reversals of impairment losses)/impairment losses on financial assets, net	**(1,222)**	2,543
Auditor's remuneration	**400**	570
Other expenses	**8,843**	6,444
	1,036,368	991,013

17 Finance costs — net

	Unaudited	
	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Interest on lease liabilities	**34,184**	42,168
Interest on borrowings	**8,343**	11,071
	42,527	53,239
Net exchange losses	**2,339**	61
Finance costs	**44,866**	53,300
Interest income	**(1,003)**	(3,214)
Finance income	**(1,003)**	(3,214)
Finance costs — net	**43,863**	50,086

18 Income tax expense

The amount of income tax expense recognised in the interim condensed consolidated statement of profit or loss represents:

	Unaudited	
	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Current income tax		
— Current period	**40,825**	46,692
— Under-provision in respect of prior years	**15,525**	18,403
Deferred income tax	**(33,207)**	(25,399)
Income tax expense	**23,143**	39,696

The corporate income tax rate applicable to the Group's subsidiaries located in mainland China is 25%. During the six months ended 30 June 2026, the corporate income tax rate applicable to some of the subsidiaries in mainland China is 15%.

19 Earnings per share

(a) Basic

Basic earnings per share is calculated by dividing the profit attributable to owners of Company by the weighted average number of ordinary shares in issue during the six months ended 30 June 2026 and 2025, respectively.

	Unaudited Six months ended 30 June	
	2026	2025
Profit attributable to owners of the Company *(RMB'000)*	**45,547**	55,941
Weighted average number of ordinary shares in issue	**1,590,124,475**	1,590,324,000
Basic earnings per share *(RMB)*	**0.03**	0.04

(b) Diluted

Diluted earnings per share is calculated by adjusting the weighted number of ordinary shares in issue for the potential dilutive effect caused by the share options granted under the share option scheme assuming they were exercised.

For the six months ended 30 June 2026 and 2025, as the average market share price of the Company's share was lower than assumed exercise price including the fair value of any services to be supplied to the Group in the future under the share option arrangement, there would be no dilutive impact.

20 Dividend

On 17 June 2026, the shareholders of the Company at the annual general meeting approved the final dividend of HK$0.02 per share for the year ended 31 December 2025, in the aggregate amount of approximately HK$31,806,000. The Board has resolved not to declare any interim dividend for the six months ended 30 June 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS OVERVIEW AND STRATEGIC OUTLOOK

Industry Overview

In 2026, China's healthcare industry entered a new stage of high-quality development led by new quality productive forces. Jointly driven by deepening medical reform policies and artificial intelligence technology, it is exhibiting three major trends: innovative breakthroughs, balanced development, and value reshaping. At the policy level, the government has continued to deepen reforms in hierarchical diagnosis and treatment and medical service pricing, promoting the allocation of high-quality medical resources to lower-level areas and ensuring balanced regional distribution. Through a new round of dynamic adjustments to the medical insurance catalog and the deepening of centralized procurement for drugs and medical devices, it has further unlocked the value of clinical innovation and delivered benefits to the public. At the technology level, large models have been deeply integrated into the entire healthcare process. AI-assisted diagnostics, intelligent comprehensive health management, and high-precision surgical robots have achieved large-scale commercialization. According to data from the National Health Commission, in 2025, the number of patient visits to primary medical and health institutions nationwide reached 5.56 billion, with the proportion increasing to 52.6%, demonstrating the continued effectiveness of the hierarchical diagnosis and treatment system. On the demand side, in the face of a deepening aging population and an upgrade in proactive health awareness across the entire population, the demand for multi-level, personalized precision medicine has surged, creating strong development momentum for the entire industry chain.

Driven by the dual forces of policy guidance and technological empowerment, the hospital sector is being compelled to shift from extensive expansion to a new track of refined and high-quality operations. Under the assurance of regularized medical compliance supervision, the industry's diagnosis and treatment ecosystem has become more transparent and clear, leading to the sustained release of demand for both essential medical treatment and high-end consumer healthcare. According to the latest data from the National Health Commission, from January to November 2025, the total number of patient visits to medical institutions nationwide reached 7.10 billion, representing a year-on-year increase of 3.3%. Of these, hospitals accounted for 4.24 billion visits, a year-on-year increase of 3.4%, with both public and private hospitals maintaining a steady growth trend.

For the medical examination industry, with the popularization of the concepts of "early screening and early diagnosis" and preventive medicine, the medical examination market has continued to expand steadily. With the increase in residents' disposable income and a stronger willingness to invest in health, the demand for in-depth specialized screenings and high-end personalized medical examination services has been further unleashed. According to data from industry research institutions, the market size of China's medical examination industry surpassed RMB370 billion in 2025, with the increase in average spending per customer and the addition of specialized testing items becoming the core engines driving growth. Moreover, the application of cutting-edge technologies such as AI-powered image screening, AI-assisted diagnosis, and AI quality control has significantly improved the precision and operational efficiency of medical examination services. This has not only given rise to innovative services such as early warnings for multiple diseases, but also accelerated the efficient linkage of the industry chain, including medical examinations with precision medicine, specialized disease management, and health insurance, driving the industry's leap towards a high-value ecosystem.

General hospital business

Nantong Rich Hospital is a large-scale general hospital integrating medical treatment, education and research. As one of the regional medical centers in Nantong, it is currently a Class III Grade B general hospital, a designated hospital for medical insurance reimbursement and a national standardized medical residency training coordination base.

On June 14, 2025, Shanghai East Hospital (East Hospital Affiliated to Tongji University) (上海市東方醫院(同濟大學附屬東方醫院)), the Nantong Economic and Technological Development Area (南通市經濟技術開發區), and Nantong Rich Hospital formally signed a strategic cooperation agreement, and on the same day inaugurated "Shanghai East Hospital Nantong Rich Hospital (上海市東方醫院南通瑞慈醫院)". On January 28, 2026, the three parties further signed an agreement to deepen their strategic cooperation, advancing the Shanghai-Nantong medical collaboration into its 2.0 phase. Shanghai East Hospital provides comprehensive management, exporting its top-tier medical technology, management models, and brand resources. During the Reporting Period, Nantong Rich Hospital, in collaboration with Shanghai East Hospital, established four benchmark centers: the Cardiovascular Center, Cerebrovascular Center, Oncology Center, and the East Rich Gallstone Center (東方瑞慈膽石中心); launched two national-level renowned doctor studios; and filled several gaps in complex local surgical procedures. In addition, the Spine Surgery Department was awarded the global "Gold Standard" certification by the International Osteoporosis Foundation (IOF).

During the Reporting Period, Nantong Rich Hospital provided services for 144,924 outpatient and emergency visits (same period in 2025: 142,777) and 11,975 inpatient visits (same period in 2025: 12,456), representing a year-on-year increase of 1.50% and a year-on-year decrease of 3.86%, respectively. Nantong Rich Hospital focused on tackling difficult Level III and IV surgeries, performing 1,918 such surgeries in the first half of the year, a year-on-year increase of 18.7%, and introduced over 30 new technologies in complex minimally invasive procedures, intracardiac interventions, radical tumor resections, and joint replacements. Its capabilities in treating acute, critical, and severe cases were significantly enhanced. The three major centers for chest pain, stroke, and trauma operated efficiently, with the volume of patients treated after being transported by "120" emergency services increasing by 8% year-on-year, and the inpatient conversion rate rising by 10%.

Located in Nantong Rich Hospital, Nantong Rich Meidi Elderly Care Centre is a joint venture formed by Nantong Rich Hospital and Medical Care Service Company Inc., which is a senior care institution combined with medical and wellness services integrating professional senior care, nursing care, and rehabilitation and physical therapy. As of June 30, 2026, the nursing home had 103 elderly residents (as of June 30, 2025: 89), with the occupancy rate increasing to 97.2% (as of June 30, 2025: 84.0%). The specialized rehabilitation hospital has completed its preparatory work and entered the acceptance phase, and is expected to officially commence operations in the near future. The implementation of the Group's integrated strategy for medical care, rehabilitation, and elderly care is accelerating, and a closed-loop, full-lifecycle health service system is beginning to take shape.

Medical examination business

The medical examination business is the core pillar of our Group's revenue. During the Reporting Period, the Group deepened its dual-brand strategic layout for "RICI HEALTH CHECKUP" and "XMEDIC", relying on differentiated positioning to precisely meet stratified health consumption demands. Among them, "RICI HEALTH CHECKUP" focuses on the mid-to-high-end mass and corporate markets, while "XMEDIC" concentrates on high-end members and precision screening. The segment adheres to a key market strategy, steadily consolidating its presence in areas with high concentrations of high-net-worth customers, such as the Yangtze River Delta, Beijing, and the Greater Bay Area, while simultaneously expanding into new first-tier and key cities. As of June 30, 2026, the Group had 80 medical examination centers in operation nationwide, covering 28 cities.

In terms of brand communication, following the title sponsorship of the Jiangsu Football City League (Jiangsu Super League) in 2025, Rici Healthcare further deepened its cooperation in 2026, becoming the "Official Event Partner and Designated Medical Service Provider for the 2026 Jiangsu Super League Nantong Division". Through various initiatives such as pre-and post-match rehabilitation support, a green channel for medical services for fans, and health education for spectators, it integrated health concepts into the public sports scene, comprehensively safeguarding the health of players and fans, and achieving a leap in high-quality brand influence.

The Group's medical examination business has always adhered to the pursuit of medical quality and high-quality services, and has been continuously committed to improving customer experience. During the Reporting Period, the Group continued to increase its investment in hardware and empowerment through cutting-edge equipment, adding 64 ultrasound units and 8 magnetic resonance imaging (MRI) machines, further strengthening the hardware support for precision screening. At the same time, during the Reporting Period, the Group comprehensively promoted the standardization of medical quality, service standardization, and digital and intelligent construction. In terms of medical quality and safety management, 4 special committees were formed and the "Tiered Standards for Critical Abnormal Findings (2026 Edition)" were revised. In the first half of 2026, the detection rate of critical abnormal findings among medical examination clients reached 9.59%, with the secondary follow-up rates for critical abnormal findings for "RICI HEALTH CHECKUP" and "XMEDIC" reaching 86.58% and 90.63%, respectively. In terms of customer service, the five-star rating for on-site services for "RICI HEALTH CHECKUP" and "XMEDIC" reached 98.35% and 99.68%, respectively. In terms of digital and intelligent empowerment, five major AI applications were implemented: AI-powered primary review, AI customer service, AI contract audit, AI group health report generation, and AI report translation. Among these, AI-powered primary review has been rolled out to all institutions nationwide, with an adoption rate of 85% for pre-generated reports, significantly enhancing operational efficiency and the level of refined services.

Outlook

The year 2026 marks a crucial starting point for the full implementation of the national "15th Five-Year" Health Plan, opening a new strategic window for the leapfrog development of the comprehensive health industry. Rici Healthcare is anchored to the grand blueprint of "Healthy China 2030" and actively responds to the national top-level design to "strengthen comprehensive prevention and control of chronic diseases and develop end-to-end services covering prevention, treatment, rehabilitation, and health management". It puts the scientific concept of "early screening, early diagnosis, and early treatment" into practice, deeply contributing to the national vision of "increasing average life expectancy by one year by 2030". Looking ahead, the Group will fully embark on a transformation and upgrade towards becoming a "technology-driven medical service group". Closely following the mid-to-long-term strategic plan of "high-quality development, cost reduction and efficiency improvement, upholding fundamental principles and innovating, and seeking progress while maintaining stability", it will comprehensively promote the steady progress of all its businesses.

In terms of general hospital and elderly care businesses, Nantong Rich Hospital will focus on "achieving Class III Grade A hospital status" as a key initiative. It will continue to deepen its cooperation with Shanghai East Hospital in specialized department development, recruitment of renowned doctors, and scientific research and training, so as to continuously increase the proportion of difficult Level III and IV surgeries and enhance its core competitiveness. It will accelerate the "one body, two wings" layout to build a comprehensive medical care, rehabilitation, and elderly care complex with a benchmark effect in the Yangtze River Delta. At the same time, it will strengthen medical insurance compliance and value creation, further promote role-based responsibility and new performance reforms, and fully stimulate internal organizational vitality.

In terms of medical examination business, the Group will, on the basis of consolidating its existing competitive advantages, continue to implement a synergistic dual-brand strategy with "RICI HEALTH CHECKUP" and "XMEDIC" to meet the diverse and personalized health management needs of consumers. As an advocate and practitioner of scientific medical examination standards, the Group will actively explore upgrading its service model from simple health check-ups to full-cycle health management. At the same time, the Group will fully leverage the precision advantages of its high-end medical equipment, accelerate the deep integration of cutting-edge technologies such as artificial intelligence with the entire medical service process, and continuously enhance its precision screening capabilities, institutional operational efficiency, and customer service level.

FINANCIAL REVIEW

Revenue

The Group's revenue was mainly generated from general hospital business and medical examination business. The following table sets forth the components of our revenue by operating segments for the periods indicated:

	Six months ended June 30,		
	2026	2025	Percentage
	RMB'000	*RMB'000*	change
General hospital business	**219,362**	234,004	(6.3%)
Medical examination business	**927,552**	925,129	0.3%
Inter-segment	**(8,336)**	(14,284)	(41.6%)
Total	**1,138,578**	1,144,849	(0.5%)

The Group's revenue for the Reporting Period amounted to RMB1,138.6 million, representing a decrease of 0.5% as compared to that of RMB1,144.8 million for the corresponding period in 2025. The year-on-year decrease in revenue during the Reporting Period was mainly attributable to the impact of external competitive pressure on the general hospital business, resulting in a decline in revenue.

Revenue from the general hospital business for the Reporting Period amounted to RMB211.0 million, representing a decrease of 4.0% from that of RMB219.7 million for the corresponding period in 2025, excluding inter-segment revenue of RMB8.3 million and RMB14.3 million for the six months ended June 30, 2026 and 2025, respectively. The decrease in revenue from the general hospital business was mainly due to the impact of external competition, as major public hospitals in the region continued to expand, diverting a portion of patients and resulting in a year-on-year decline in revenue.

Revenue from the medical examination business for the Reporting Period amounted to RMB927.6 million, representing an increase of 0.3% from that of RMB925.1 million for the corresponding period in 2025. The growth was mainly attributable to the increase in revenue from the "XMEDIC" brand, a high-end medical examination business line, as compared to the corresponding period of last year.

Cost of Sales

The Group's cost of sales primarily consists of pharmaceuticals and medical consumables costs, staff costs and depreciation and amortization expenses. The following table sets forth an analysis of cost of sales by operating segments for the periods indicated:

	Six months ended June 30,		
	2026	2025	Percentage
	RMB'000	*RMB'000*	change
General hospital business	**184,752**	201,037	(8.1%)
Medical examination business	**565,059**	550,506	2.6%
Inter-segment	**(8,336)**	(14,284)	(41.6%)
Total	**741,475**	737,259	0.6%

The Group's cost of sales for the Reporting Period amounted to RMB741.5 million, representing an increase of 0.6% from that of RMB737.3 million for the corresponding period in 2025.

Cost of sales from the general hospital business for the Reporting Period amounted to RMB184.8 million, representing a decrease of 8.1% from that of RMB201.0 million for the corresponding period in 2025. The decrease in cost of sales of the general hospital business during the Reporting Period was mainly due to the decrease in revenue of the general hospital business during the Reporting Period.

Cost of sales from the medical examination business for the Reporting Period amounted to RMB565.1 million, representing an increase of 2.6% from that of RMB550.5 million for the corresponding period in 2025. The increase in cost of sales of the medical examination business during the Reporting Period was mainly due to the increase in its revenue.

Gross Profit

The Group's gross profit decreased from RMB407.6 million for the six months ended June 30, 2025 to RMB397.1 million for the Reporting Period. Gross profit margin decreased by 0.7 percentage points from 35.6% for the six months ended June 30, 2025 to 34.9% for the Reporting Period.

Distribution Costs and Selling Expenses

The Group's distribution costs and selling expenses for the Reporting Period amounted to RMB190.3 million, as compared to RMB134.5 million for the corresponding period in 2025. The increase was mainly because the Company built up its sales talent pool for the medical examination business, leading to a corresponding increase in staff costs and an increase in promotional expenses.

Administrative Expenses

The Group's administrative expenses for the Reporting Period amounted to RMB105.8 million, representing a decrease as compared to that of RMB116.7 million for the corresponding period in 2025.

Other Income

The Group's other income, which is mainly comprised of government subsidies, amounted to RMB23.2 million during the Reporting Period (corresponding period in 2025: RMB21.0 million).

Other Losses

The Group's other losses for the Reporting Period amounted to RMB0.1 million, as compared to that of RMB5.9 million for the corresponding period in 2025. Other losses during the Reporting Period were mainly represented by losses on disposal of equipment and other miscellaneous losses.

Finance Costs — Net

Our finance costs — net amounted to RMB43.9 million during the Reporting Period, as compared to that of RMB50.1 million for the corresponding period in 2025. This was primarily due to interest expenses of approximately RMB42.5 million, exchange losses of approximately RMB2.3 million, and interest income of RMB1.0 million incurred during the Reporting Period.

Share of Results of Investments Accounted for Using Equity Method

For the Reporting Period, the Group recognised a share of loss of RMB0.3 million from investments accounted for using equity method (corresponding period in 2025: share of profit of RMB0.6 million) in its consolidated results.

Income Tax Expense

For the Reporting Period, income tax expense amounted to RMB23.1 million (corresponding period in 2025: income tax expense of RMB39.7 million).

Profit for the Period

As a result of the above, the Group reported a net profit of RMB65.1 million for the Reporting Period (corresponding period in 2025: a net profit of RMB79.7 million).

Adjusted EBITDA

To supplement our interim condensed consolidated financial information which are presented in accordance with HKAS 34 Interim Financial Reporting, we use adjusted EBITDA as an additional financial measure. We define adjusted EBITDA as profit for the period before certain expenses and depreciation and amortization as set out in the table below. Adjusted EBITDA is not an alternative to (i) profit before income tax or profit for the period (as determined in accordance with HKFRSs) as a measure of our operating performance; (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs; or (iii) any other measures of performance or liquidity. The following table reconciles our profit for the periods under HKFRSs to our definition of adjusted EBITDA for the periods indicated.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Calculation of adjusted EBITDA		
Profit for the Period	**65,136**	79,745
Adjustments to the following items:		
Income tax expense	**23,143**	39,696
Finance costs — net	**43,863**	50,086
Depreciation and amortization	**204,006**	211,436
Pre-opening expenses and EBITDA loss of soft-opening[1]	**3,749**	5,636
Adjusted EBITDA	**339,897**	386,599
Adjusted EBITDA margin[2]	**29.9%**	33.8%

Notes:

(1) Primarily represents (a) the pre-opening expenses, such as staff costs and rental expenses, incurred in the applicable period in connection with the construction of medical examination centers; and (b) the EBITDA loss incurred during the period when the newly opened medical examination centers commenced their operations.

(2) The calculation of adjusted EBITDA margin is based on adjusted EBITDA divided by revenue and multiplied by 100%.

The adjusted EBITDA amounted to RMB339.9 million during the Reporting Period, representing a decrease of 12.1% as compared to that of RMB386.6 million for the corresponding period in 2025, mainly due to the decrease in revenue from the general hospital business, resulting in a decrease in profit.

FINANCIAL POSITION

Property and Equipment

Property and equipment primarily consist of buildings, medical equipment, general equipment, leasehold improvements and construction in progress. As at June 30, 2026, the property and equipment of the Group amounted to RMB1,379.9 million, representing a decrease of RMB42.9 million as compared to that of RMB1,422.8 million as at December 31, 2025.

Trade Receivables

As at June 30, 2026, the trade receivables of the Group amounted to RMB247.4 million, representing a decrease of RMB38.7 million as compared to RMB286.1 million as at December 31, 2025.

Net Current Liabilities

As at June 30, 2026, the Group's current liabilities exceeded its current assets by RMB85.8 million (as at December 31, 2025: RMB44.4 million). The increase in the Group's net current liabilities was mainly due to capital cash expenditures for the acquisition of medical equipment during the Reporting Period.

Liquidity and Capital Resources

As at June 30, 2026, the Group had cash and cash equivalents of RMB1,065.3 million (as at December 31, 2025: RMB1,135.4 million), with available unused bank facilities of RMB290.0 million (as at December 31, 2025: RMB321.0 million). As at June 30, 2026, the Group had outstanding borrowings of RMB570.0 million (as at December 31, 2025: RMB635.6 million), with non-current portion of long-term borrowings of RMB224.9 million (as at December 31, 2025: RMB242.5 million). Based on the Group's past experience and good credit standing, the Directors are confident that such bank facilities could be renewed or extended for at least 12 months upon maturity. We adopt prudent treasury policies in cash and financial management to achieve better risk control, manage financial resources efficiently and minimize the cost of funds. For the currency in which cash and cash equivalents are denominated, please refer to Note 8 to the interim condensed consolidated financial information. As of June 30, 2026, the Group had not used any financial instruments for hedging purposes.

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, the Group did not have any significant investment, material acquisition or material disposal.

Future Plans for Material Investments and Capital Asset

Save as disclosed in this report, as of June 30, 2026, the Group did not have detailed future plans for material investments and capital assets.

Capital Expenditure and Commitments

For the Reporting Period, the Group incurred capital expenditures of RMB166.2 million (corresponding period in 2025: RMB175.1 million), primarily for (i) purchases of medical equipment as well as renovation for the Group's medical examination centers; and (ii) the lease of business premises for new medical examination centers.

As at June 30, 2026, the Group had a total capital commitment of RMB19.7 million (as at December 31, 2025: RMB30.4 million), mainly comprising leasehold improvement.

Borrowings

As at June 30, 2026, the Group had total bank and other borrowings of RMB570.0 million (as at December 31, 2025: RMB635.6 million). All the borrowings are denominated in RMB. Please refer to Note 11 to the interim condensed consolidated financial information for more details.

Contingent Liabilities

The Group had no material contingent liability as at June 30, 2026 (as at December 31, 2025: Nil).

Gearing Ratio

As at June 30, 2026, on the basis of net debt divided by total capital, the Group's gearing ratio was 32.9% (as at December 31, 2025: 33.8%).

Cash Flow and Fair Value Interest Rate Risk

Our exposure to changes in interest rates is mainly attributable to our bank borrowings and lease liabilities.

Borrowings obtained at variable rates expose us to cash flow interest rate risk. Borrowings obtained at fixed rates expose us to fair value interest rate risk. As at June 30, 2026, borrowings of RMB570,025,000 were with floating interest rates (as at December 31, 2025: RMB635,600,000). We did not hedge our cash flow and fair value interest rate risk during the Reporting Period.

Foreign Exchange Risk

For the Reporting Period, the Group was not exposed to significant foreign currency risk, except for bank deposits denominated in Hong Kong dollar and United States dollar. The Group currently does not have a foreign currency hedging policy. However, the management closely monitors foreign exchange exposure and will consider hedging significant foreign exchange exposure should the need arise.

Credit Risk

We have no significant concentration of credit risk. The carrying amount of cash and cash equivalents, trade and other receivables and deposits from long-term leases represent our maximum exposure to credit risk in relation to our financial assets. The objective of our measures to manage credit risk is to control potential exposure to recoverability problem.

Cash and cash equivalents were deposited in the major financial institutions, which the directors believe are of high credit quality.

The Group has policies in place to ensure that receivables with credit terms are made to counterparties with an appropriate credit history and the management performs ongoing credit evaluations of the counterparties. The credit period granted to the customers and the credit quality of these customers are assessed, with reference to their financial position, past experience and available forward-looking information. The Group considers the probability of default upon initial recognition of a financial asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. The Group also considers available reasonable and supportive forward-looking information.

The credit risk of hospital business is related to the recoverability of trade receivables and other receivables. The credit risk of medical examination business is related to the length of the overdue period of trade receivables from corporate customers and other receivables.

Liquidity Risk

Our finance department monitors rolling forecasts of our liquidity requirements to ensure that we have sufficient cash to meet operational needs while maintaining sufficient headroom on our undrawn borrowing facilities at all times so that we do not breach borrowing limits or covenants (where applicable) on any of our borrowing facilities. We expect to fund the future cash flow needs through cash flows generated from operations, borrowings from financial institutions and issuing debt instruments or capital contribution from the shareholders of the Company (the "**Shareholders**"), as necessary. Based on contractual undiscounted payments, our financial liabilities were RMB2,639.7 million as at June 30, 2026 (as at December 31, 2025: RMB2,772.4 million).

Pledge of Assets

As at June 30, 2026, the Group had assets with a total carrying amount of RMB666,132,000 (as at December 31, 2025: assets of RMB693,350,000) pledged for the Group's borrowings.

HUMAN RESOURCES

The Group had a total of 8,542 (December 31, 2025: 8,523) employees as of June 30, 2026. The employee benefits expenses were approximately RMB552 million for the Reporting Period and RMB469 million for the corresponding period in 2025. The Group enters into employment contracts with its employees to cover matters such as position, term of employment, wage, employee benefits and liabilities for breaches and grounds for termination. Remuneration of the Group's employees includes basic salaries, allowances, bonus, share option scheme and other employee benefits, and is determined with reference to their experience, qualifications and general market conditions. The emolument policy for the employees of the Group is set up by the Board on the basis of their merit, qualification and competence. We provide regular training to our employees in order to improve their skills and knowledge. The training courses range from further educational studies to skill training to professional development courses for management personnel, including a management trainee program.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the Reporting Period (for the six months ended June 30, 2025: Nil).

CORPORATE GOVERNANCE PRACTICES

The Company recognises the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the code provisions as set out in the Corporate Governance Code (the "**CG Code**") as contained in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), as its own code to govern its corporate governance practices.

In the opinion of the Directors, the Company has complied with the relevant code provisions contained in the CG Code during the Reporting Period, save for deviation from code provisions C.1.7 and C.2.1 of the CG Code.

Code provision C.1.7 of the CG Code provides that appropriate insurance cover in respect of legal action against directors should be arranged. For the Reporting Period, the Company did not have insurance cover for legal action against the Directors. However, pursuant to the Company's articles of association, the Directors shall be indemnified and secured harmless out of the assets and profits of the Company from and against all actions, costs, charges, losses, damages and expenses which they or any of them shall or may incur or sustain by or by reason of any act done, concurred in or omitted in or about the execution of their duty, or supposed duty, in their respective offices. In view of the above, the Board considers that the Directors' exposure to litigation risk is manageable even if there is no insurance cover for legal action against the Directors.

Pursuant to code provision C.2.1 of the CG Code, the responsibility between the chairman and the chief executive officer should be segregated and should not be performed by the same individual. However, the Company does not have a separate chairman and the chief executive officer and Dr. Fang Yixin ("**Dr. Fang**") performs these two roles. The Board considers that vesting the roles of the chairman and the chief executive officer in Dr. Fang is beneficial to the Group for implementing its new business strategies given his abundant experience in the healthcare industry and longtime and substantive involvement in the day to day management and operation of the Group. In addition, the balance of power and authority is ensured by the operation of the Board and the senior management, which comprises experienced and capable individuals independent from Dr. Fang (except his spouse, Dr. Mei Hong, and his son, Mr. Fang Haoze). The Board comprised four executive Directors and three independent non-executive Directors as at the date of this announcement and has a fairly strong independence element in its composition.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Group's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Directors have been granted the general mandate (the "**Repurchase Mandate**") pursuant to resolutions of the Shareholders passed on June 17, 2026, to repurchase shares of the Company in the open market from time. Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 10% of the total number of issued shares of the Company (excluding treasury shares if any) as at the date of passing such resolution.

From January to June 2026, the Company cumulatively repurchased 1,899,000 shares at the lowest and highest purchase prices of HK$0.66 and HK$0.93 per share, respectively, for a total purchase amount of HK$1,452,890. Such repurchased shares were held as treasury shares. Details of the share repurchases are summarized as follows:

		Repurchased price per share		
Month of repurchase	**Total number of shares repurchased**	**Lowest** *(HK$)*	**Highest** *(HK$)*	**Aggregate consideration** *(HK$)*
May 2026	147,000	0.66	0.71	101,110
June 2026	1,752,000	0.69	0.93	1,351,780

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including treasury shares) during the Reporting Period.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The audit committee of the Board, comprising Ms. Wong Sze Wing, Mr. Jiang Peixing and Mr. Tian Wenguo, has discussed with the management and reviewed the unaudited interim condensed consolidated financial information of the Group for the Reporting Period.

PUBLICATION OF RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange at ***www.hkexnews.hk*** and on the website of the Company at ***www.rich-healthcare.com***. The interim report of the Company for the Reporting Period containing all the information required by the Listing Rules will be dispatched to the Shareholders and published on the above websites in due course.

APPRECIATION

On behalf of the Board, I would like to thank all our colleagues for their diligence, dedication, loyalty and integrity. I would also like to thank all our Shareholders, customers, bankers and other business associates for their trust and support.

By Order of the Board
Rici Healthcare Holdings Limited
Fang Yixin
Chairman and Chief Executive Officer

Shanghai, the PRC, August 28, 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Dr. Fang Yixin, Dr. Mei Hong, Mr. Fang Haoze and Ms. Lin Xiaoying; and three independent non-executive Directors, namely Mr. Jiang Peixing, Ms. Wong Sze Wing and Mr. Tian Wenguo.